Lymphatic Malformation Clinical Trials

9 recruiting

Frequently Asked Questions

Common questions about Lymphatic Malformation clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 2Phase 3

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

Lymphatic Malformations
Novartis Pharmaceuticals232 enrolled49 locationsNCT05948943
Recruiting
Phase 2

Weekly Sirolimus Therapy

Lymphatic MalformationVenous Malformation
Medical University of South Carolina24 enrolled1 locationNCT04861064
Recruiting
Phase 2

A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations

PI3K Gene MutationVascular AnomaliesArteriovenous Malformations+11 more
Murdoch Childrens Research Institute50 enrolled2 locationsNCT05983159
Recruiting
Not Applicable

A Prospective Study on the Treatment of cLM Based on ICG Imaging

Lymphatic Malformation
Nanjing Children's Hospital110 enrolled1 locationNCT06275022
Recruiting
Phase 3

Systematic Approach for Children With Orbital Malformation With Sirolimus Use

Orbital Lymphatic Malformation
Ain Shams University30 enrolled1 locationNCT07378657
Recruiting
Phase 2

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

PIK3CA MutationVascular MalformationsPIK3CA-Related Overgrowth Spectrum (PROS)+4 more
Relay Therapeutics, Inc.277 enrolled25 locationsNCT06789913
Recruiting
Phase 2

Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations

PediatricLymphatic Malformation
University Hospital, Lille28 enrolled2 locationsNCT03243019
Recruiting
Phase 2

Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

Lymphatic Malformation
Protara Therapeutics38 enrolled10 locationsNCT05871970
Recruiting
Not Applicable

Institution of an Italian Registry and Biobank for Biological Sample Collection

Lymphatic AbnormalitiesLymphatic MalformationLymphatic Abnormality+1 more
Fondazione Policlinico Universitario Agostino Gemelli IRCCS70 enrolled1 locationNCT06892964
Recruiting
Phase 2Phase 3

Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations

Lymphatic Malformation
West China Hospital150 enrolled1 locationNCT06673290
Recruiting

Lymphatic Anomalies Registry for the Assessment of Outcome Data

Lymphatic MalformationCLOVES SyndromeKaposiform Lymphangiomatosis+5 more
Boston Children's Hospital1,000 enrolled1 locationNCT02399527
Recruiting
Phase 2

Use of Bleomycin in the Sclerotherapy of Lymphatic Malformations for Pediatric Patients

Lymphatic Malformation
West China Hospital200 enrolled1 locationNCT06437158
Recruiting
Phase 1

5 year study of 6 children each year with vascular anomalies who have severe complications failing to respond to the usual treatments will be offered a new use of an old medication- sirolimus

PIKC3A related overgrowth syndrome (PROS)Vascular tumours (tufted angiomas and kaposiform haemangioendotheliomas)Complex lymphatic malformations+2 more
Sydney Children's Hospital, Randwick30 enrolled1 locationACTRN12616000943448